Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
- Target Recruit Count
- 38
- Registration Number
- NCT00722930
- Locations
- 🇪🇸
Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain
🇪🇸Hospital Virgen de la Salud de Toledo, Toledo, Spain
🇪🇸Clínica Ruber Internacional, Madrid, Spain
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 149
- Registration Number
- NCT00662948
- Locations
- 🇪🇸
Hospital Dr Pesset, Valencia, Spain
🇪🇸Hospital La Paz, Madrid, Spain
🇪🇸Hospital Doce de Octubre, Madrid, Spain
Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Target Recruit Count
- 20
- Registration Number
- NCT00644371
- Locations
- 🇪🇸
H. Santa Creu i Sant Pau., Barcelona, Barcelona., Spain
🇪🇸Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸H.U. Gregorio Marañón, Madrid, Spain
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
- Conditions
- Mantle Cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 31
- Registration Number
- NCT00607854
- Locations
- 🇫🇷
Hématologie et Oncologie médicale - CHU Lapeyronie, Montpellier, France
🇫🇷Pôle hématologie et immunologie clinique - Hôpital Saint-Louis, Paris, France
🇫🇷Service d'hématologie - CHU de Besançon, Besançon, France
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
- Conditions
- LymphomaDiffuse Large Cell Lymphoma
- Interventions
- Procedure: Stem Cell Transplant
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00591630
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 18
- Registration Number
- NCT00582166
- Locations
- 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
- Conditions
- Primary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT00521560
- Locations
- 🇩🇪
Institut für anwendungsorientierte Forschung und klinische Studien (IFS GmbH), Göttingen, Germany
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- CABYC
- Target Recruit Count
- 30
- Registration Number
- NCT00505232
- Locations
- 🇪🇸
Clinica Moncloa, Madrid, Spain
🇪🇸Hospital Quiron, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00493467
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00493454
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.